Adcytherix Secures Major Funding to Propel Therapeutic Pipeline
Adcytherix SAS, a burgeoning name in the biopharmaceutical sector, has successfully completed a funding round amounting to €105 million (approximately US$122 million) in Series A financing. This strategic financial move aims to expedite the development of their promising pipeline of antibody-drug conjugates (ADCs) focused on treating challenging cancers.
Leading Investors Driving the Financing Round
The Series A round was spearheaded by Bpifrance, in collaboration with Kurma Partners, Andera Partners, and Angelini Ventures. This collective of investors was joined by prestigious newcomers such as Surveyor Capital, a Citadel company, and aMoon, along with renewed support from existing shareholders like Pontifax, DawnBiopharma, Pureos Bioventures, and RA Capital.
Advancing ADCX-020 and Other Key Programs
The proceeds from this funding round will not only support Adcytherix's lead candidate, ADCX-020, as it moves towards clinical development, but also enable the exploration of additional innovative ADCs. The company has laid ambitious plans to submit its first investigational new drug (IND) applications in the United States and clinical trial applications (CTA) in Europe, the UK, and Canada by the end of 2025.
Commentary from the Leadership Team
Jack Elands, the CEO and founder of Adcytherix, expressed his enthusiasm regarding the funding, stating, "Closing the largest ADC-focused Series A in Europe validates our science, our vision, and the exceptional work of our team. We are proud to have attracted a world-class syndicate of investors who share our ambition to develop groundbreaking ADCs for patients who are resistant to other treatments."
Strategic Importance of Novel Payloads in Cancer Treatment
The primary focus for Adcytherix will be the integration of innovative payloads into its ADCs. This strategy is designed to launch targeted therapies that can more effectively tackle cancers with high unmet needs, potentially revolutionizing treatment options for patients.
Welcoming a New Supervisory Committee
As part of the financing arrangements, key investors such as Olivier Martinez and Laurent Higueret from Bpifrance, and Peter Neubeck from Kurma Partners will sit on the new Supervisory Committee, which will also include experts from various associated investors. This diverse team aims to guide the strategic direction of Adcytherix as it continues to grow.
About Adcytherix and Its Vision
Founded by a skilled team including Jack Elands, Adcytherix is geared towards creating pioneering ADCs to tackle cancers where treatment gaps exist. With a strong support system from leading life science investors, the company is positioned to emerge as a prominent player in the ADC arena and make transformative contributions to cancer care.
Frequently Asked Questions
What is the main goal of Adcytherix's new funding?
The primary aim is to push their lead candidate ADCX-020 into clinical trials and to further develop innovative antibody-drug conjugates based on novel payloads.
Who are the key investors in Adcytherix's Series A funding?
The funding round was led by Bpifrance, with contributions from Kurma Partners, Andera Partners, Angelini Ventures, and other prestigious investors.
When does Adcytherix plan to file for clinical trials?
Adcytherix plans to submit its first investigational new drug (IND) and clinical trial applications (CTA) by the end of 2025.
What differentiates Adcytherix in the ADC market?
Adcytherix focuses on developing ADCs with unique payloads aimed at addressing cancers that currently have limited treatment options.
Where is Adcytherix located?
Adcytherix is headquartered in Marseille, France, and has subsidiaries in the United States and the Netherlands.
